




RealRate

PHARMACEUTICAL 2019

Unity Biotechnology Inc.
Rank 169 of 371

UNITY
BIOTECHNOLOGY



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Unity Biotechnology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unity Biotechnology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 276% points. The greatest weakness of Unity Biotechnology Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is -132%, being 199% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	172,965
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,582
Liabilities, Non-Current	45
Other Assets	2,172
Other Compr. Net Income	9.0
Other Expenses	4,787
Other Liabilities	4,055
Other Net Income	3,312
Property and Equipment	6,238
Research and Development	58,907
Revenues	0
Selling, General and Administrative Expense	16,016

Output Variable	Value in 1000 USD
Assets	181,375
Liabilities	20,682
Expenses	79,710
Stockholders Equity	160,693
Net Income	-76,398
Comprehensive Net Income	-76,394
Economic Capital Ratio	-132%